

23347

PATENT TRADEMARK OFFICE

10/031637
531 Rec'd PCT/... 26 OCT 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Michael Birsha DAVIES, et al

US Natinal Serial No.: To Be Assigned

Group Art Unit:

Filed:

Examiner:

International Serial Number: PCT/EP00/03515

Filed : 19 April 2000

For: MEDICAMENT CARRIER

Commissioner for Patents
Washington, D.C. 20231**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [] Copies of the references are enclosed:
 [] Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
 [x] A copy of the International Search Report which issued on International Application No.
PCT/EP00/03515 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 (1) a final action under § 1.113 or
 (2) a notice of allowance under § 1.311,
 whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

10/031637

531 Rec'd PCT/FT 26 OCT 2001

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,



Attorney of Record: Christopher P. ROGERS
Registration No. 36,334

24 Oct 2001
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1240
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG3693USW	SERIAL NO. (Intern'l) PCT/EP00/03515
APPLICANT: Michael Birsha DAVIES et al		
FILING (Intern'l) 19 April 2000	GROUP	

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	US3698 549A	17 October 1972	Glassman, Jacob A.			
	AB	US3 724 651 A	3 April 1973	Link, M			
	AC	US2 968 396A	17 January 1961	Pratt			
	AD	US 6 024 732 A	15 February 2000	Samuelsson Ann			
	AE	US 5 077 104 A	21 December 1989	Hunt			
	AF	US 5 590 645A	7 January 1997	Davies Micael Birsha et al			
		-					

Continue on page

FOREIGN PATENT DOCUMENTS

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.